Manufacturers: Evommune Inc.
Evommune's first-in-class, potent and highly selective oral small molecule MRGPRX2 antagonist; failed Phase 2b in moderate-to-severe atopic dermatitis and will not be advanced in that indication, while Phase 2b development continues in migraine prophylaxis.
Evommune's first-in-class, potent and highly selective oral small molecule MRGPRX2 antagonist; failed Phase 2b in moderate-to-severe atopic dermatitis and will not be advanced in that indication, while Phase 2b development continues in migraine prophylaxis.
Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist
2 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
